1. Indolfi G., Easterbrook P., Dusheiko G., El-Sayed M.H., Jonas M.M., Thorne C., et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019; 4 (6): 477–87. DOI: https://doi. org/10.1016/S2468-1253(19)30046-9
2. WHO. Global hepatitis report, 2017. Geneva: World Health Organization, 2017.
3. Pawlowska M., Sobolewska-Pilarczyk M., Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol. 2018; 24 (24): 2555–66. DOI: https://doi.org/10.3748/wjg.v24.i24.2555
4. Dhiman R.K., Grover G.S., Premkumar M., Taneja S., Duseja A., Rathi S., Satsangi S. Direct-acting antiviral therapy is safe and effective in pediatric chronic hepatitis C: the public health Perspective. J Pediatr Gastroenterol Nutr. 2019; 68 (1): 74–80. DOI: https://doi.org/10.1097/ MPG.0000000000002139
5. El-Shabrawi M., Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol. 2019; 20 (3): 163–74. DOI: https://doi.org/10.1016/j.ajg.2019.09.003
6. Razavi H., El-Sayed M. Updated global estimate of HCV infection in the pediatric population. 2016. http://cdafound.org/content/ Downloads/ Pediatric%20Prevalence%20161201.pdf (date of access: July 18, 2021)
7. Mizuochi T., Takano T., Yanagi T., Ushijima K., Suzuki M., Miyoshi Y., et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018; 53 (3): 419–26.
8. Bortolotti F., Muratori L., Jara P., et al. Hepatitis C virus infection associated with liver-kidney microsomal antibody type 1 (LKM1) autoantibodies in children. J Pediatr. 2003; 142 (2): 185–90.
9. Modin L., Arshad A., Wilkes B., et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol. 2019; 70 (3): 371–8.
10. Guido M., Bortolotti F., Leandro G., Jara P., Hierro L., Larrauri J., et al. Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? Am J Gastroenterol. 2003; 98 (3): 660–3. DOI: https://doi. org/10.1111/j.1572-0241.2003.07293.x
11. Indolfi G., Guido M., Azzari C., Resti M. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev Anti Infect Ther. 2015; 13 (10): 1225–35. DOI: https://doi.org/10.1586/14787210.2015.1070668
12 Goodman Z.D., Makhlouf H.R., Liu L., et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008; 47 (3): 836–43. DOI: https://doi.org/10.1002/hep.22094
13. Cesaro S., Petris M.G., Rossetti F., et al. Chronic hepatitis C virus infection after treatment for pediatric malignancy. Blood. 1997; 90 (3): 1315–20. DOI: https://doi.org/10.1182/blood.V90.3.1315
14. Turkova A. The European Paediatric HIV/ HCV Co-infection Study Group in European Pregnancy and Paediatric HIV Cohort Collaboration. Uptake and outcomes of HCV treatment in children and young adults with HIV/ HCV co-infection in Europe. 20th International AIDS Conference; 20–25 July 2014, Melbourne, Australia.
15. Malik S., Dekio F., Wen J.W. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of posttransplant viral recurrence using boceprevir. Pediatr Transplant. 2014; 18 (2): E64–8. DOI: https://doi.org/10.1111/petr.122232
16. González-Peralta R.P., Langham M.R.Jr., Andres J.M., Mohan P., Colombani P.M., Alford M.K., Schwarz K.B. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr. 2009; 48 (5): 630–5. DOI: https://doi.org/10.1097/MPG.0b013e318170af04
17. Rodrigue J.R., Balistreri W., Haber B., Jonas M.M., Mohan P., Molleston J.P., et al. Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes. J Pediatr Gastroenterol Nutr. 2009; 48 (3): 341–7. DOI: https://doi.org/10.1097/ MPG.0b013e318185998f
18. Nydegger A., Srivastava A., Wake M., Smith A.L., Hardikar W. Health-related quality of life in children with hepatitis C acquired in the first year of life. J Gastroenterol Hepatol. 2008; 23 (2): 226–30. DOI: https:// doi.org/10.1111/j.1440-1746.2007.04859.x
19. Morales A., Vallejo-Medina P., Abello-Luque D., et al. Sexual risk among Colombian adolescents: knowledge, attitudes, normative beliefs, perceived control, intention, and sexual behavior. BMC Public Health. 2018; 18 (1): 1377. DOI: https://doi.org/10.1186/s12889-018-6311-y
20. Forsyth S., Rogstad K. Sexual health issues in adolescents and young adults [published correction appears in Clin Med (Lond). 2015. Vol. 15, N 6. P. 565]. Clin Med (Lond). 2015; 15 (5): 447–51. DOI: https://doi.org/10.7861/clinmedicine.15-5-447
21. Goryacheva L.G., Rogozina N.V., Shilova I.V., Karev V.E., Greshnyakova V.A .Diagnostics and treatment of chronic hepatitis in children. Medical benefit. St. Petersburg, 2016. (in Russian)
22. González-Peralta R.P., Kelly D.A., Haber B., et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology. 2005; 42 (5): 1010–8. DOI: https://doi.org/10.1002/hep.20884
23. Goriacheva L.G., Greshniakova V.A. Cascade plazmofiltration in complex therapy of chronic hepatitides at children. In the collection: Current issues of hepatology: experimental hepatology, therapeutic hepatology, surgical hepatology: Materials of the XI International Symposium of Belarusian Hepatologists, Grodno, October 2, 2015, Grodno: Grodno State Medical University, 2015: 33–6. (in Russian)
24. Balistreri W.F., Murray K.F., Rosenthal P., et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2017; 66 (2): 371–8. DOI: https://doi.org/10.1002/hep.28995
25. Wirth S., Rosenthal P., Gonzalez-Peralta R.P., et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2017; 66 (4): 1102–10. DOI: https://doi. org/10.1002/hep.29278
26. Murray K.F., Balistreri W.F., Bansal S., Whitworth S., Evans H.M., Gonzalez-Peralta R.P., et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6–11. Hepatology. 2018; 68 (6): 2158–66. DOI: https://doi.org/10.1002/hep.30123
27. Jonas M.M., Squires R.H., Rhee S.M., Lin C.W., Bessho K., FeiternaSperling C., et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in pediatric patients with genotypes 1–6 chronic HCV infection: Part 1 of the Dora Study. Hepatology. 2018; 68 (suppl): 1347A–8A.
28. Volynets G.V. A modern view on the treatment of chronic hepatitis C in children and adolescents. Rossiyskiy Vestnik Perinatologii i Pediatrii [Russian Bulletin of Perinatology and Pediatrics]. 2019; 64 (6): 11–9. DOI: https://doi.org/10.21508/1027-4065-2019-64-6-11-19 (in Russian)
29. Harris H.E., Mieli-Vergani G., Kelly D., Davison S., Gibb D.M., Ramsay M.E.; HCV National Register Steering Group. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr. 2007; 45 (3): 335–41. DOI: https://doi.org/10.1097/MPG.0b013e3180dc9337 3
30. Iorio R., Giannattasio A., Sepe A., Terracciano L.M., Vecchione R., Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005; 41 (10): 1431–7. DOI: https://doi.org/10.1086/497141
31. Mohan P., Barton B.A., Narkewicz M.R., Molleston J.P., GonzalezPeralta R.P., Rosenthal P., et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C – a retrospective study. Hepatology. 2013; 58 (5): 1580–6. DOI: https://doi.org/10.1002/hep.26519
32. Camma C., Di Bonna D., Schepis F., Heathcote E.J., Zeuzem S., Pockros P.J., et al. Effect of peginterferon alfa-2a on liver histology in peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology. 2004; 39 (2): 333–42. DOI: https:// doi.org/10.1002/hep.20073
33. Rodríguez-Torres M., Rodríguez-Orengo J.F., Ríos-Bedoya C.F., Fernández-Carbia A., Marxuach-Cuétara A.M., López-Torres A., JiménezRivera J. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: A paired liver biopsy study. J Hepatol. 2007; 46 (4): 613–9. DOI: https://doi.org/10.1016/j.jhep.2006.12.011
34. Chan J., Gogela N., Zheng H., Lammert S., Ajayi T., Fricker Z., et al. Direct-acting antiviral therapy for chronic HCV infection results in liver stiffness regression over 12 months post-treatment. Dig Dis Sci. 2018; 63 (2): 486-92. DOI: https://doi.org/10.1007/s10620-017-4749-x
35. Bachofner J.A., Valli P.V., Kröger A., Bergamin I., Künzler P., Baserga A., et al. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers Fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017; 37 (3): 369–76.
36. Tada T., Kumada T., Toyoda H., Mizuno K., Sone Y., Kataoka S., et al. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017; 32 (12): 1982–8. DOI: https://doi.org/10.1111/jgh.13788
37. Fahmy D.M., Shokeir M., El Zeiny S.M., Jonas M.M., Abdallah A. Changes in liver stiffness and noninvasive fibrosis scores in Egyptian adolescents successfully treated with ledipasvir-sofosbuvir for chronic hepatitis C virus infection. J Pediatr. 2021; 231: 110–6. DOI: https://doi. org/10.1016/j.jpeds.2020.12.031